Evolus, Inc. (EOLS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -166.67%. A quarter ago, it was expected that this company would post a loss of $0.1 per share when it actually produced a loss of $0.18, delivering a surprise of -80%.Over the last four quarters, the company has not been a ...

Evolus (EOLS) Q2 2025 Earnings Call August 05, 2025 04:30 PM ET Speaker0Good afternoon, everyone, and thank you for standing by. Welcome to Evolus Second Quarter Earnings Conference Call. As a reminder, today's conference is being recorded and webcast live. All participants are in a listen only mode. After the speakers' remarks, there will be a question and answer session.I would now like to turn the conference over to Narek Segarian, Vice President and Head of Global Investor Relations and Corporate Commun ...

Commission File Number: 001-38381 EVOLUS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tra ...

INVESTOR PRESENTATION AUGUST 2025 2 DISCLOSURES FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product and p ...

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates NEWPORT BEACH, Calif., August 5, 2025 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2025. "U.S. toxin demand softened in the second quarter, driven by reduced patient demand due to a sharp decrease in consumer sentiment which resulted in accounts purchasing lower volumes ...

Group 1 - The article discusses the importance of staying updated on stocks in the biotech, pharma, and healthcare sectors, highlighting the potential for investment opportunities driven by key trends and catalysts [1] - Evolus (NASDAQ: EOLS) has been previously covered with a "Buy" recommendation issued in March 2024, which has been reiterated in a more recent note [1] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including product sales forecasts, integrated financial statements, and market analysis [1] Group 2 - The author, Edmund Ingham, has over 5 years of experience in covering biotech, healthcare, and pharma, having prepared detailed reports on more than 1,000 companies [1]

Financial Performance and Goals - Evolus aims to achieve over 20% non-GAAP operating income with at least $700 million in revenue by 2028[10] - The company is targeting $700 million in global sales by 2028, representing a 28% CAGR from 2023[20] - Evolus expects to launch Evolysse and gain approval within the next 12 months[10] - The company's revenue guidance for 2024 is between $260 million and $270 million[21] Market and Product Expansion - The total addressable market for injectables is projected to reach $10 billion by 2028[20] - Evolus plans to expand internationally to achieve $100 million in international revenue by 2028[23] - The company has filed for filler approval with a launch planned in the second half of 2025[23] Clinical Study Results - In a Phase III study, Jeuveau demonstrated non-inferiority to Botox, with responder rates of 87.2% for Jeuveau and 82.8% for Botox at day 30[38] - A post-hoc analysis of a Phase III clinical study showed comparable results between Jeuveau and Botox in improving glabellar line scale and subject satisfaction[44, 48] Evolysse Dermal Fillers - US NLF pivotal study results for Evolysse Form vs Restylane-L showed non-inferiority at 6 months[120] - US NLF pivotal study results for Evolysse Smooth vs Restylane-L also met the primary endpoint of non-inferiority at 6 months[128]

Market and Growth - The total addressable market expands by 78% with the addition of injectable HA gel portfolio[16] - The neurotoxin market is growing to $6 billion in 2028, with a 13% CAGR from 2023[21] - The fillers market is growing to approximately $4 billion in 2028, with a 10% CAGR from 2023[21] - Evolus International is expected to achieve $100 million in 2028[23] Financial Performance and Projections - Evolus expects total net revenues for 2025 to be between $345 million and $355 million[28,112] - Q4 2024 net revenue reached $79 million, a 30% year-over-year increase[106] - The company projects at least $700 million total net revenue by 2028[113,115] - The company projects a non-GAAP operating income margin of at least 20% by 2028[113,115] Product and Strategy - Jeuveau's share of the toxin market has grown from 4% in 2019 to 13% in 2024[19] - 70% of toxin consumers also use a dermal filler[71] - Evolus Rewards program has approximately 1.1 million total enrollments[59,107]

Core Insights - Evolus, Inc. reported a quarterly loss of $0.18 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, marking an earnings surprise of -80% [1] - The company's revenues for the quarter ended March 2025 were $68.52 million, missing the Zacks Consensus Estimate by 4.83%, but showing an increase from $59.33 million year-over-year [2] - Evolus has not surpassed consensus EPS estimates over the last four quarters and has only topped revenue estimates once in that same period [2] Company Performance - Evolus shares have increased by approximately 5.2% since the beginning of the year, contrasting with a -4.7% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $82.86 million, and for the current fiscal year, it is -$0.01 on revenues of $351.43 million [7] Earnings Outlook - The estimate revisions trend for Evolus is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The outlook for the Medical - Products industry, to which Evolus belongs, is in the bottom 28% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Financial Data and Key Metrics Changes - Evolus reported global net revenue of $68.5 million for Q1 2025, representing a 15.5% increase compared to Q1 2024, supported by a strong commercial engine [6][15][12] - The company achieved a gross margin of 68.1% and an adjusted gross margin of 69.2% for the first quarter [18] - Non-GAAP operating loss for Q1 was $500,000, an improvement from a loss of $900,000 in Q1 2024, with expectations of achieving profitability in Q4 2025 [21][28] Business Line Data and Key Metrics Changes - Product revenue accounted for approximately 94% of total sales, with a customer reorder rate of about 70% [15] - The company added 675 new purchasing accounts, bringing the total to over 16,000, indicating strong market penetration [7] - The loyalty program saw over 220,000 redemptions, with 65% from existing consumers, highlighting high consumer satisfaction [8] Market Data and Key Metrics Changes - Evolus gained a 14% market share by the end of 2024, exceeding initial guidance, and continued to gain share in Q1 2025 [17] - International revenue contribution increased and is expected to outpace U.S. growth, validating the strong growth trajectory of the toxin business outside the U.S. [16] - The company reduced its toxin market growth expectation to low single digits for 2025, reflecting a more conservative outlook [6][17] Company Strategy and Development Direction - Evolus is transitioning into a multiproduct company with the launch of Evolisse, aiming to redefine the category and capture market share [8][11] - The company is focused on building long-term customer relationships and deepening its presence within existing accounts [11] - Evolus aims to achieve total net revenue of at least $700 million by 2028, with a compounded annual growth rate of 27% from 2024 [24][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a challenging market environment while maintaining growth [14][12] - The early success of Evolisse is seen as a momentum builder, reinforcing growth across the portfolio [12] - Management reiterated full-year revenue guidance of $345 million to $355 million, projecting continued growth above 30% [27][28] Other Important Information - The company has taken proactive steps to strengthen its balance sheet through debt refinancing, reducing interest expenses and increasing cash generation [22][23] - Evolus is closely monitoring tariff impacts on its products, with limited exposure expected for 2025 [18][19] Q&A Session Summary Question: Market trends and demand changes - Management indicated that both macroeconomic factors and negative sentiment around the term "filler" are impacting demand, but they see an opportunity to revive the market segment [30][32] Question: Impact of AbbVie's loyalty program changes - Management acknowledged the impact of AbbVie's loyalty program changes on market dynamics but believes they continue to gain share despite this [44][46] Question: Confidence in 2025 revenue guidance - Management reiterated confidence in 2025 guidance due to accelerated share uptake despite slower market growth [54][56] Question: Early adopters of Evolisse - The initial adoption of Evolisse is primarily among existing customers, with high interest in trialing the product [65][66] Question: Seasonality and market softness - Management noted a consistent seasonal pattern but acknowledged slight slowing in new patient starts, impacting overall market dynamics [70][78]